Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Meghna Ailawadhi"'
Autor:
Sikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Mizba Baksh, Ahsan Rasheed, Saurav Das, Andre J. Fernandez, Aneel Paulus, Asher A. Chanan‐Khan
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19013-19020 (2023)
Abstract Introduction Health information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial‐ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization.
Externí odkaz:
https://doaj.org/article/1a893cfa3efb441eb05f8da1cd56f354
Autor:
Shehzad Niazi, Ryan D. Frank, Mayank Sharma, Vivek Roy, Steve Ames, Teresa Rummans, Aaron Spaulding, Taimur Sher, Meghna Ailawadhi, Kirtipal Bhatia, Salman Ahmed, Winston Tan, Asher Chanan-Khan, Sikander Ailawadhi
Publikováno v:
Blood Advances, Vol 2, Iss 10, Pp 1120-1128 (2018)
Abstract: Approximately one third of cancer patients suffer from comorbid mood disorders that are associated with increased cost and poorer outcomes. The majority of patients with multiple myeloma (MM) are treated with corticosteroids; as many as thr
Externí odkaz:
https://doaj.org/article/7bfa02fadb5445c6bba63fcc9a2307cb
Autor:
Sharad Khurana, Salman Ahmed, Victoria R Alegria, Sonikpreet Aulakh, Meghna Ailawadhi, Anshika Singh, Asher Chanan-Khan, Sikander Ailawadhi
Publikováno v:
SAGE Open Medical Case Reports, Vol 7 (2019)
Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukem
Externí odkaz:
https://doaj.org/article/6958fce5ba264a41b5ac4702f7018277
Autor:
Mizba Baksh, Aneel Paulus, Meghna Ailawadhi, Vivek Roy, Navnita Dutta, Gerson Quintero, Asher Chanan-Khan, Chander Shekher Aggarwal, Vivek Kumar, Mays F Abdulazeez, Victoria R. Alegria, Sikander Ailawadhi, Taimur Sher
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e449-e455
Despite significant improvements in multiple myeloma (MM) treatment modalities, patient mortality early in the course of disease has been identified as a persistent phenomenon with variable reported rates and causes. Trends in early mortality over ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad29845f5075f4cb20df5c037de9cf68
https://doi.org/10.1016/j.clml.2020.12.023
https://doi.org/10.1016/j.clml.2020.12.023
Autor:
Asher Chanan-Khan, Aneel Paulus, David O. Hodge, Taimur Sher, Mark A. Fiala, Meghna Ailawadhi, Vivek Roy, Chander Shekher Aggarwal, Prachi Jani, Mays F Abdulazeez, Salman Ahmed, Victoria R. Alegria, Sonikpreet Aulakh, Ryan D. Frank, Sikander Ailawadhi, Zahara Kanji
Publikováno v:
Annals of Hematology. 100:735-741
Plasma cell disorders including plasmacytomas and multiple myeloma (MM) are exquisitely radiosensitive, and thus, radiation therapy (XRT) is used effectively in their management. The role of XRT in the setting of novel MM therapeutics has not been ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ae919708b481ca6145b844950e7a96
https://doi.org/10.1007/s00277-020-04371-1
https://doi.org/10.1007/s00277-020-04371-1
Autor:
Sikander Ailawadhi, Jay R. Hydren, Leyla Bojanini, Nathan W. Sweeney, Felicia Seng, Mizba Baksh, Ahsan Rasheed, Mays Abdulazeez, Meghna Ailawadhi, Keren George, Ricardo D Parrondo, Vivek Roy, Victoria R. Alegria, Pooja Advani, Rami Manochakian, Jason S. Starr, Taimur Sher, Jennifer M. Ahlstrom, Asher Chanan-Khan
Publikováno v:
Blood. 140:7941-7942
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbd009a9a73cde7ab3e3080b5fb01add
https://doi.org/10.1182/blood-2022-167005
https://doi.org/10.1182/blood-2022-167005
Autor:
Mays F Abdulazeez, Abdel Ghani Azzouqa, Meghna Ailawadhi, Vivek Roy, Prakash Vishnu, Victoria R. Alegria, Asher Chanan-Khan, David O. Hodge, Rami Manochakian, Aneel Paulus, Jordan J. Cochuyt, Prachi Jani, Sikander Ailawadhi, Taimur Sher, Salman Ahmed, Ashna Grover
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:619-623
Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4d454e82965e9d44bda56dd92864469
https://doi.org/10.1016/j.clml.2019.06.010
https://doi.org/10.1016/j.clml.2019.06.010
Autor:
Aditya Mehta, Prakash Vishnu, Asher Chanan-Khan, Rami Manochakian, Suman Biswas, Aneel Paulus, Taimur Sher, Leyla Bojanini, Julian A. Marin-Acevedo, Sonikpreet Aulakh, Sikander Ailawadhi, Victoria R. Alegria, Meghna Ailawadhi, Vivek Roy, Madiha Iqbal, Winston Tan, Vivek Kumar
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 10, Pp 1-10 (2019)
Blood Cancer Journal
Blood Cancer Journal
With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences in risk for SPMs among CLL survivors from the Surveillance, Epidemiology, and End Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::644ddd6915f1decec05fc2813881611e
http://link.springer.com/article/10.1038/s41408-019-0237-1
http://link.springer.com/article/10.1038/s41408-019-0237-1
Autor:
Asher Chanan-Khan, Mays F Abdulazeez, Meghna Ailawadhi, Vivek Roy, Srilekha Bodepudi, Shahrukh K. Hashmi, Abhisek Swaika, Victoria R. Alegria, Nandita Khera, Sikander Ailawadhi, David O. Hodge, Taimur Sher, Aneel Paulus, Khushi Jamwal, Pooja Advani
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(2)
Objective Outcomes in multiple myeloma (MM) have significantly improved necessitating focus on survivorship. Methods We undertook a web-based survey in collaboration with International Myeloma Foundation (IMF) to explore patient awareness and psycho-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::205132217919403a9c23a9ca71aa24c7
https://pubmed.ncbi.nlm.nih.gov/33719723
https://pubmed.ncbi.nlm.nih.gov/33719723
Autor:
Kirtipal Bhatia, Asher Chanan-Khan, Winston Tan, Shehzad K. Niazi, Salman Ahmed, Teresa A. Rummans, Meghna Ailawadhi, Vivek Roy, Mayank Sharma, Ryan D. Frank, Aaron Spaulding, Taimur Sher, Steve Ames, Sikander Ailawadhi
Publikováno v:
Blood Advances. 2:1120-1128
Approximately one third of cancer patients suffer from comorbid mood disorders that are associated with increased cost and poorer outcomes. The majority of patients with multiple myeloma (MM) are treated with corticosteroids; as many as three fourths
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a4953bca86216c01ab7aa642d777e5
https://doi.org/10.1182/bloodadvances.2018016717
https://doi.org/10.1182/bloodadvances.2018016717